Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gambro beats Fresenius in Australia patent case:

This article was originally published in Clinica

Executive Summary

An Australian federal court has ruled that Fresenius's dialysis concentrate and monitoring systems infringe a patent owned by Gambro subsidiary Gambro Lundia. The patent covers the BiCart dry concentrate system. Fresenius has been banned from distributing its biBag product in Australia, and damages due to Gambro will be assessed. However, Fresenius may appeal and the enforcement of the injunction will be stayed until the appeal has been decided. Dry concentrate systems are designed to reduce the risk of contamination and bacterial growth associated with liquid bicarbonate concentrates, and account for about 20% of the worldwide concentrate market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel